U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
  • Quoted phrase not found.

Retinal disorder

MedGen UID:
11209
Concept ID:
C0035309
Disease or Syndrome
Synonyms: Retinal Diseases; Retinopathies; Retinopathy
SNOMED CT: Retinopathy (29555009); Retinal disorder (29555009); Retinal disease (29555009)
 
HPO: HP:0000488
Monarch Initiative: MONDO:0005283

Definition

Any noninflammatory disease of the retina. This nonspecific term is retained here because of its wide use in the literature, but if possible new annotations should indicate the precise type of retinal abnormality. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRetinal disorder

Conditions with this feature

Abetalipoproteinaemia
MedGen UID:
1253
Concept ID:
C0000744
Disease or Syndrome
Abetalipoproteinemia typically presents in infancy with failure to thrive, diarrhea, vomiting, and malabsorption of fat. Hematologic manifestations may include acanthocytosis (irregularly spiculated erythrocytes), anemia, reticulocytosis, and hemolysis with resultant hyperbilirubinemia. Malabsorption of fat-soluble vitamins (A, D, E, and K) can result in an increased international normalized ratio (INR). Untreated individuals may develop atypical pigmentation of the retina that may present with progressive loss of night vision and/or color vision in adulthood. Neuromuscular findings in untreated individuals including progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle weakness; dysarthria; and ataxia typically manifest in the first or second decades of life.
Hb SS disease
MedGen UID:
287
Concept ID:
C0002895
Disease or Syndrome
Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a "splenic sequestration." The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections, primarily encapsulated organisms. Acute chest syndrome (ACS) is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation as well as activating pathways that contribute to the pathophysiology directly. Individuals with the highest rates of hemolysis are at higher risk for pulmonary artery hypertension, priapism, and leg ulcers and may be relatively protected from vaso-occlusive pain.
Pseudo-Hurler polydystrophy
MedGen UID:
10988
Concept ID:
C0033788
Disease or Syndrome
GNPTAB-related disorders comprise the phenotypes mucolipidosis II (ML II) and mucolipidosis IIIa/ß (ML IIIa/ß), and phenotypes intermediate between ML II and ML IIIa/ß. ML II is evident at birth and slowly progressive; death most often occurs in early childhood. Orthopedic abnormalities present at birth may include thoracic deformity, kyphosis, clubfeet, deformed long bones, and/or dislocation of the hip(s). Growth often ceases in the second year of life; contractures develop in all large joints. The skin is thickened, facial features are coarse, and gingiva are hypertrophic. All children have cardiac involvement, most commonly thickening and insufficiency of the mitral valve and, less frequently, the aortic valve. Progressive mucosal thickening narrows the airways, and gradual stiffening of the thoracic cage contributes to respiratory insufficiency, the most common cause of death. ML IIIa/ß becomes evident at about age three years with slow growth rate and short stature; joint stiffness and pain initially in the shoulders, hips, and fingers; gradual mild coarsening of facial features; and normal to mildly impaired cognitive development. Pain from osteoporosis becomes more severe during adolescence. Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left and/or right ventricular hypertrophy) are common causes of death, typically in early to middle adulthood. Phenotypes intermediate between ML II and ML IIIa/ß are characterized by physical growth in infancy that resembles that of ML II and neuromotor and speech development that resemble that of ML IIIa/ß.
Primary hyperoxaluria, type I
MedGen UID:
75658
Concept ID:
C0268164
Disease or Syndrome
Primary hyperoxaluria type 1 (PH1) is caused by a deficiency of the liver peroxisomal enzyme alanine:glyoxylate-aminotransferase (AGT), which catalyzes the conversion of glyoxylate to glycine. When AGT activity is absent, glyoxylate is converted to oxalate, which forms insoluble calcium oxalate crystals that accumulate in the kidney and other organs. Individuals with PH1 are at risk for recurrent nephrolithiasis (deposition of calcium oxalate in the renal pelvis / urinary tract), nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), or end-stage renal disease (ESRD). Age at onset of symptoms ranges from infancy to the sixth decade. Approximately 10% of affected individuals present in infancy or early childhood with nephrocalcinosis, with or without nephrolithiasis, and failure to thrive related to renal failure. The majority of individuals with PH1 present in childhood or early adolescence, usually with symptomatic nephrolithiasis and normal or reduced kidney function. The remainder of affected individuals present in adulthood with recurrent renal stones and a mild-to-moderate reduction in kidney function. The natural history of untreated PH1 is one of progressive decline in renal function as a result of calcium oxalate deposits in kidney tissue and complications of nephrolithiasis (e.g., obstruction and infection) with eventual progression to oxalosis (widespread tissue deposition of calcium oxalate) and death from ESRD and/or complications of oxalosis.
Hyperphosphatasemia with bone disease
MedGen UID:
75678
Concept ID:
C0268414
Disease or Syndrome
Paget disease of bone-5 is an autosomal recessive, juvenile-onset form of Paget disease, a disorder of the skeleton resulting from abnormal bone resorption and formation. Clinical manifestations include short stature, progressive long bone deformities, fractures, vertebral collapse, skull enlargement, and hyperostosis with progressive deafness. There is phenotypic variability, with some patients presenting in infancy, while others present later in childhood (summary by Naot et al., 2014). For discussion of genetic heterogeneity of Paget disease of bone, see 167250.
Juvenile nephropathic cystinosis
MedGen UID:
75701
Concept ID:
C0268626
Congenital Abnormality
Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.
NARP syndrome
MedGen UID:
231285
Concept ID:
C1328349
Disease or Syndrome
Mitochondrial DNA (mtDNA)-associated Leigh syndrome and NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) are part of a continuum of progressive neurodegenerative disorders caused by abnormalities of mitochondrial energy generation. Leigh syndrome (or subacute necrotizing encephalomyelopathy) is characterized by onset of symptoms typically between ages three and 12 months, often following a viral infection. Decompensation (often with elevated lactate levels in blood and/or CSF) during an intercurrent illness is typically associated with psychomotor retardation or regression. Neurologic features include hypotonia, spasticity, movement disorders (including chorea), cerebellar ataxia, and peripheral neuropathy. Extraneurologic manifestations may include hypertrophic cardiomyopathy. About 50% of affected individuals die by age three years, most often as a result of respiratory or cardiac failure. NARP is characterized by proximal neurogenic muscle weakness with sensory neuropathy, ataxia, and pigmentary retinopathy. Onset of symptoms, particularly ataxia and learning difficulties, is often in early childhood. Individuals with NARP can be relatively stable for many years, but may suffer episodic deterioration, often in association with viral illnesses.
Congenital disorder of glycosylation type 1E
MedGen UID:
324784
Concept ID:
C1837396
Disease or Syndrome
Congenital disorders of glycosylation (CDGs) are metabolic deficiencies in glycoprotein biosynthesis that usually cause severe mental and psychomotor retardation. Different forms of CDGs can be recognized by altered isoelectric focusing (IEF) patterns of serum transferrin. For a general discussion of CDGs, see CDG Ia (212065) and CDG Ib (602579).
Neuronal ceroid lipofuscinosis 7
MedGen UID:
325457
Concept ID:
C1838571
Disease or Syndrome
The neuronal ceroid lipofuscinoses (NCL, or CLN) are a clinically and genetically heterogeneous group of neurodegenerative disorders characterized by the intracellular accumulation of autofluorescent lipopigment storage material in different patterns ultrastructurally (summary by Mole et al., 2005). For a general phenotypic description and a discussion of genetic heterogeneity of CLN, see CLN1 (256730).
Late-onset retinal degeneration
MedGen UID:
344198
Concept ID:
C1854065
Disease or Syndrome
Late-onset retinal degeneration (LORD) is an autosomal dominant disorder characterized by onset in the fifth to sixth decade with night blindness and punctate yellow-white deposits in the retinal fundus, progressing to severe central and peripheral degeneration, with choroidal neovascularization and chorioretinal atrophy (Hayward et al., 2003).
Bardet-Biedl syndrome 11
MedGen UID:
395295
Concept ID:
C1859569
Disease or Syndrome
Bardet-Biedl syndrome-11 (BBS11) is a pleiotropic autosomal recessive disorder characterized by obesity, pigmentary retinopathy, polydactyly, renal abnormalities, learning disabilities, and hypogenitalism (Chiang et al., 2006). For a general phenotypic description and a discussion of genetic heterogeneity of Bardet-Biedl syndrome, see BBS1 (209900).
Karsch-Neugebauer syndrome
MedGen UID:
401072
Concept ID:
C1866740
Disease or Syndrome
A rare syndrome with characteristics of split-hand and split-foot deformity and ocular abnormalities mainly a congenital nystagmus. Ten cases from four families have been reported in the literature. In some cases the hands are monodactylous. The affected patients have normal mental development. The condition seems to be autosomal dominant with a relatively high proportion of gonadal mosaicism.
Dominant pericentral pigmentary retinopathy
MedGen UID:
357237
Concept ID:
C1867261
Disease or Syndrome
A retinitis pigmentosa that is characterized pigmentary retinal degeneration with onset in the teens leading to blindness in the sixth ans seventh decades of life.
Nephropathic cystinosis
MedGen UID:
419735
Concept ID:
C2931187
Disease or Syndrome
Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.
Hereditary spastic paraplegia 48
MedGen UID:
462251
Concept ID:
C3150901
Disease or Syndrome
Spastic paraplegia-48 (SPG48) is an autosomal recessive neurologic disorder characterized by spasticity of the lower limbs resulting in gait difficulties. Most patients have onset in mid- or late-adulthood, although childhood onset has been reported in 1 patient. Additional features may include parkinsonism, urinary incontinence, neuropathy, and mild cognitive impairment (summary by Hirst et al., 2015). For a discussion of genetic heterogeneity of autosomal recessive SPG, see SPG5A (270800).
Joubert syndrome 15
MedGen UID:
482527
Concept ID:
C3280897
Disease or Syndrome
Classic Joubert syndrome (JS) is characterized by three primary findings: A distinctive cerebellar and brain stem malformation called the molar tooth sign (MTS). Hypotonia. Developmental delays. Often these findings are accompanied by episodic tachypnea or apnea and/or atypical eye movements. In general, the breathing abnormalities improve with age, truncal ataxia develops over time, and acquisition of gross motor milestones is delayed. Cognitive abilities are variable, ranging from severe intellectual disability to normal. Additional findings can include retinal dystrophy, renal disease, ocular colobomas, occipital encephalocele, hepatic fibrosis, polydactyly, oral hamartomas, and endocrine abnormalities. Both intra- and interfamilial variation are seen.
Joubert syndrome 20
MedGen UID:
767149
Concept ID:
C3554235
Disease or Syndrome
Classic Joubert syndrome (JS) is characterized by three primary findings: A distinctive cerebellar and brain stem malformation called the molar tooth sign (MTS). Hypotonia. Developmental delays. Often these findings are accompanied by episodic tachypnea or apnea and/or atypical eye movements. In general, the breathing abnormalities improve with age, truncal ataxia develops over time, and acquisition of gross motor milestones is delayed. Cognitive abilities are variable, ranging from severe intellectual disability to normal. Additional findings can include retinal dystrophy, renal disease, ocular colobomas, occipital encephalocele, hepatic fibrosis, polydactyly, oral hamartomas, and endocrine abnormalities. Both intra- and interfamilial variation are seen.
Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2
MedGen UID:
767448
Concept ID:
C3554534
Disease or Syndrome
Mitochondrial complex IV deficiency nuclear type 6 (MC4DN6) is an autosomal recessive multisystem metabolic disorder with a highly variable phenotype. Some patients present in the neonatal period with encephalomyopathic features, whereas others present later in the first year of life with developmental regression. Manifestations include hypotonia, feeding difficulties, and global developmental delay. Many, but not all, patients develop hypertrophic cardiomyopathy, which may result in early death. Additional more variable features may include poor overall growth, microcephaly, seizures, neurodegeneration, spasticity, visual defects, retinopathy, and hepatic steatosis. Brain imaging in some patients shows features consistent with Leigh syndrome (see 256000). Laboratory studies show increased serum lactate and decreased levels and activity of mitochondrial respiratory complex IV (summary by Kennaway et al., 1990 and Oquendo et al., 2004). For a discussion of genetic heterogeneity of mitochondrial complex IV (cytochrome c oxidase) deficiency, see 220110.
Joubert syndrome 21
MedGen UID:
816542
Concept ID:
C3810212
Disease or Syndrome
Classic Joubert syndrome (JS) is characterized by three primary findings: A distinctive cerebellar and brain stem malformation called the molar tooth sign (MTS). Hypotonia. Developmental delays. Often these findings are accompanied by episodic tachypnea or apnea and/or atypical eye movements. In general, the breathing abnormalities improve with age, truncal ataxia develops over time, and acquisition of gross motor milestones is delayed. Cognitive abilities are variable, ranging from severe intellectual disability to normal. Additional findings can include retinal dystrophy, renal disease, ocular colobomas, occipital encephalocele, hepatic fibrosis, polydactyly, oral hamartomas, and endocrine abnormalities. Both intra- and interfamilial variation are seen.
Microcephaly and chorioretinopathy 2
MedGen UID:
863825
Concept ID:
C4015388
Disease or Syndrome
Microcephaly and chorioretinopathy-2 is an autosomal recessive developmental disorder characterized by delayed psychomotor development, visual impairment, and short stature (summary by Martin et al., 2014). For a discussion of genetic heterogeneity of microcephaly and chorioretinopathy, see MCCRP1 (251270).
Joubert syndrome 27
MedGen UID:
934673
Concept ID:
C4310706
Disease or Syndrome
Classic Joubert syndrome (JS) is characterized by three primary findings: A distinctive cerebellar and brain stem malformation called the molar tooth sign (MTS). Hypotonia. Developmental delays. Often these findings are accompanied by episodic tachypnea or apnea and/or atypical eye movements. In general, the breathing abnormalities improve with age, truncal ataxia develops over time, and acquisition of gross motor milestones is delayed. Cognitive abilities are variable, ranging from severe intellectual disability to normal. Additional findings can include retinal dystrophy, renal disease, ocular colobomas, occipital encephalocele, hepatic fibrosis, polydactyly, oral hamartomas, and endocrine abnormalities. Both intra- and interfamilial variation are seen.
Meckel syndrome 13
MedGen UID:
1627793
Concept ID:
C4539714
Disease or Syndrome
Orofaciodigital syndrome 16
MedGen UID:
1620071
Concept ID:
C4539729
Disease or Syndrome
Odontochondrodysplasia 2 with hearing loss and diabetes
MedGen UID:
1782909
Concept ID:
C5543275
Disease or Syndrome
Odontochondrodysplasia-2 with hearing loss and diabetes (ODCD2) is characterized by growth retardation with proportionate short stature, dentinogenesis imperfecta, sensorineural hearing loss, insulin-dependent diabetes, and mild intellectual disability (Cauwels et al., 2005; Lekszas et al., 2020). For a discussion of genetic heterogeneity of ODCD, see ODCD1 (184260).
Spinocerebellar ataxia, autosomal recessive 31
MedGen UID:
1786855
Concept ID:
C5543627
Disease or Syndrome
Autosomal recessive spinocerebellar ataxia-31 (SCAR31) is a complex neurodevelopmental disorder characterized by global developmental delay with hypotonia and variably impaired intellectual and language development. Affected individuals have an ataxic gait, tremor, and dysarthria; more severely affected patients also have spasticity with inability to walk. Most have optic atrophy. Brain imaging shows cerebellar hypoplasia, enlarged ventricles, and atrophy of the posterior corpus callosum. Additional features may include retinitis pigmentosa, sensorineural deafness, dysmorphic facial features, and possibly endocrine dysfunction (summary by Collier et al., 2021).
Combined oxidative phosphorylation deficiency 29
MedGen UID:
1799030
Concept ID:
C5567607
Disease or Syndrome
A rare mitochondrial oxidative phosphorylation disorder with characteristics of microcephaly, global developmental delay, spastic-dystonic movement disorder, intractable seizures, optic atrophy, autonomic dysfunction and peripheral neuropathy. Serum lactate is increased, and muscle biopsy shows decreased activity of mitochondrial respiratory complexes I and III. Brain imaging reveals progressive cerebellar atrophy and delayed myelination.
Intellectual developmental disorder, X-linked 112
MedGen UID:
1840225
Concept ID:
C5829589
Disease or Syndrome
X-linked intellectual disorder-112 (XLID112) is a neurodevelopmental disorder characterized by developmental delay, with speech delay more prominent than motor delay, autism or autism traits, and variable dysmorphic features. Affected females have been reported, which appears to be related to skewed X-inactivation (summary by Hiatt et al., 2023).

Professional guidelines

PubMed

Gudiseva HV, Berry JL, Polski A, Tummina SJ, O'Brien JM
Genes (Basel) 2019 Dec 11;10(12) doi: 10.3390/genes10121032. PMID: 31835688Free PMC Article
Ho CPS, Lai TYY
Indian J Ophthalmol 2018 Dec;66(12):1727-1735. doi: 10.4103/ijo.IJO_975_18. PMID: 30451173Free PMC Article
Shams Najafabadi H, Daftarian N, Ahmadieh H, Soheili ZS
Arch Iran Med 2017 Aug;20(8):525-537. PMID: 28846017

Recent clinical studies

Etiology

Matsevich C, Gopalakrishnan P, Chang N, Obolensky A, Beryozkin A, Salameh M, Kostic C, Sharon D, Arsenijevic Y, Banin E
Mol Ther 2023 Oct 4;31(10):2948-2961. Epub 2023 Aug 14 doi: 10.1016/j.ymthe.2023.08.011. PMID: 37580905Free PMC Article
Ge G, Zhang Y, Zhang Y, Xu Z, Zhang M
Graefes Arch Clin Exp Ophthalmol 2020 Jan;258(1):71-77. Epub 2019 Nov 16 doi: 10.1007/s00417-019-04486-w. PMID: 31734720
Bashinsky AL
N C Med J 2017 Mar-Apr;78(2):124-128. doi: 10.18043/ncm.78.2.124. PMID: 28420777
Bhavsar KV, Lin S, Rahimy E, Joseph A, Freund KB, Sarraf D, Cunningham ET Jr
Surv Ophthalmol 2016 Sep-Oct;61(5):538-65. Epub 2016 Mar 10 doi: 10.1016/j.survophthal.2016.03.003. PMID: 26973287
Do DV, Gichuhi S, Vedula SS, Hawkins BS
Cochrane Database Syst Rev 2013 Dec 19;12(12):CD006366. doi: 10.1002/14651858.CD006366.pub3. PMID: 24357418Free PMC Article

Diagnosis

Zhu J, Huang J, Sun Y, Xu W, Qian H
Theranostics 2024;14(4):1631-1646. Epub 2024 Feb 4 doi: 10.7150/thno.92463. PMID: 38389842Free PMC Article
Bashinsky AL
N C Med J 2017 Mar-Apr;78(2):124-128. doi: 10.18043/ncm.78.2.124. PMID: 28420777
Bhavsar KV, Lin S, Rahimy E, Joseph A, Freund KB, Sarraf D, Cunningham ET Jr
Surv Ophthalmol 2016 Sep-Oct;61(5):538-65. Epub 2016 Mar 10 doi: 10.1016/j.survophthal.2016.03.003. PMID: 26973287
Zobor D, Zobor G, Kohl S
Ophthalmic Res 2015;54(2):103-8. Epub 2015 Aug 21 doi: 10.1159/000435957. PMID: 26304472
Campos E
Surv Ophthalmol 1995 Jul-Aug;40(1):23-39. doi: 10.1016/s0039-6257(95)80044-1. PMID: 8545799

Therapy

Tatsumi T
Int J Mol Sci 2023 May 31;24(11) doi: 10.3390/ijms24119591. PMID: 37298544Free PMC Article
Song W, Zhu YW
Chin J Integr Med 2019 Apr;25(4):316-320. Epub 2018 Sep 28 doi: 10.1007/s11655-017-2911-0. PMID: 30264267
Do DV, Gichuhi S, Vedula SS, Hawkins BS
Cochrane Database Syst Rev 2018 Jan 10;1(1):CD006366. doi: 10.1002/14651858.CD006366.pub4. PMID: 29364503Free PMC Article
Behar-Cohen F, Zhao M
Curr Opin Neurol 2016 Feb;29(1):49-54. doi: 10.1097/WCO.0000000000000284. PMID: 26679569
Do DV, Gichuhi S, Vedula SS, Hawkins BS
Cochrane Database Syst Rev 2013 Dec 19;12(12):CD006366. doi: 10.1002/14651858.CD006366.pub3. PMID: 24357418Free PMC Article

Prognosis

Zhu J, Huang J, Sun Y, Xu W, Qian H
Theranostics 2024;14(4):1631-1646. Epub 2024 Feb 4 doi: 10.7150/thno.92463. PMID: 38389842Free PMC Article
Kumar SVM, Gunasundari R
Med Biol Eng Comput 2023 Mar;61(3):593-615. Epub 2023 Jan 3 doi: 10.1007/s11517-022-02737-3. PMID: 36595155
Vishnoi A, Rani S
Methods Mol Biol 2017;1509:1-10. doi: 10.1007/978-1-4939-6524-3_1. PMID: 27826912
Quimson SK
Neonatal Netw 2015;34(5):284-7. doi: 10.1891/0730-0832.34.5.284. PMID: 26802829
Iacono P, Battaglia Parodi M, Falcomatà B, Bandello F
Ophthalmic Res 2015;55(2):76-83. Epub 2015 Dec 1 doi: 10.1159/000441502. PMID: 26619293

Clinical prediction guides

Arsenijevic Y, Chang N, Mercey O, El Fersioui Y, Koskiniemi-Kuendig H, Joubert C, Bemelmans AP, Rivolta C, Banin E, Sharon D, Guichard P, Hamel V, Kostic C
EMBO Mol Med 2024 Apr;16(4):805-822. Epub 2024 Mar 19 doi: 10.1038/s44321-024-00053-x. PMID: 38504136Free PMC Article
Kumar SVM, Gunasundari R
Med Biol Eng Comput 2023 Mar;61(3):593-615. Epub 2023 Jan 3 doi: 10.1007/s11517-022-02737-3. PMID: 36595155
Iacono P, Toto L, Costanzo E, Varano M, Parravano MC
Curr Pharm Des 2018;24(41):4864-4873. doi: 10.2174/1381612825666190123165914. PMID: 30674250
Vishnoi A, Rani S
Methods Mol Biol 2017;1509:1-10. doi: 10.1007/978-1-4939-6524-3_1. PMID: 27826912
Iacono P, Battaglia Parodi M, Falcomatà B, Bandello F
Ophthalmic Res 2015;55(2):76-83. Epub 2015 Dec 1 doi: 10.1159/000441502. PMID: 26619293

Recent systematic reviews

Li J, Huang Z, Jin Y, Liang L, Li Y, Xu K, Zhou W, Li X
Curr Neuropharmacol 2024;22(8):1374-1390. doi: 10.2174/1570159X21666230907152207. PMID: 37691227Free PMC Article
Cota F, Costa S, Giannantonio C, Purcaro V, Catenazzi P, Vento G
J Matern Fetal Neonatal Med 2022 Jan;35(1):175-180. Epub 2020 Feb 10 doi: 10.1080/14767058.2020.1712700. PMID: 32041442
Do DV, Gichuhi S, Vedula SS, Hawkins BS
Cochrane Database Syst Rev 2018 Jan 10;1(1):CD006366. doi: 10.1002/14651858.CD006366.pub4. PMID: 29364503Free PMC Article
Kirkegaard K, Heegaard S, Hvas AM
Acta Ophthalmol 2017 Feb;95(1):12-19. Epub 2016 Aug 29 doi: 10.1111/aos.13214. PMID: 27573507
Do DV, Gichuhi S, Vedula SS, Hawkins BS
Cochrane Database Syst Rev 2013 Dec 19;12(12):CD006366. doi: 10.1002/14651858.CD006366.pub3. PMID: 24357418Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity